Business
Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day
Phase 3 COVE Study: Updated cases show continued strong efficacy, including greater than 90% against cases of COVID-19 and greater than 95% against severe
About this update from Moderna, Inc.
[{"type":"text","content":"\nPhase 3 COVE Study: Updated cases show continued strong efficacy, including greater than 90% against cases of COVID-19 and greater than 95% against severe cases of COVID-19, with approximately 6 months median follow-up post dose 2\n\nAntibody persistence data out to 6 months published in The New England Journal of Medicine\n\nNew preclinical data shows variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increase neutralizing titers against SARS-CoV-2 variants of concern\n\nSupply Update: As of April 12, approximately 132 million doses have been delivered globally\n\nVaccines Day to be held on Wednesday, April 14 at 8:00 a.m. ET\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nModerna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced clinical and supply updates on its COVID-19 Vaccine program. New results from a preclinical study of the Company’s COVID-19 variant-specific vaccine candidates showed that the Company’s variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increase neutralizing titers against SARS-CoV-2 variants of concern. To date, the Company has delivered approximately 132 million doses of the Moderna COVID-19 Vaccine globally.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413006131/en/To date, over 132 million doses of Moderna's COVID-19 vaccine have been delivered to the U.S. and around the world. (Graphic: Business Wire)\n“The Moderna team continues to make important progress with our COVID-19 Vaccine. We are looking forward to having the clinical data from our variant-specific booster candidates, as well as clinical data from the Phase 2/3 study of our COVID-19 Vaccine in adolescents,” said Stéphane Bancel, Chief Executive Officer of Moderna. “The new preclinical data on our variant-specific vaccine candidates give us confidence that we can proactively address emerging variants. Moderna will make as many updates to our COVID-19 vaccine as necessary until the pandemic is under control.”\n\nUpdate on the Phase 3 COVE Study of the Moderna COVID-19 Vaccine\n\nToday, the Company is sharing an update on the Phase 3 COVE study of the Moderna COVID-19 Vaccine (mRNA-1273). An updated review of adjudicated cases has identified over 900 cases...